Medical Advocates
Lopinavir/Ritonavir (Kaletra/Aluvia)
 
Pediatric Indications: Efficacy

LPV/RTV
 LPV/RTV/D4T/3TC 
LPV/RTV/EFV
 LPV/RTV/Multiple Regimens
Salvage Therapy





 

KLS Main Page

Home

 
Last Update:  April 03, 2008
Posters identified with this icon are in Portable Document Format (PDF) and require the  Adobe Acrobat Reader

LPV/RTV Studies
       
     Journal Papers, Abstracts, and Commentaries
 
 
Long-Term Safety and Effectiveness of Ritonavir, Nelfinavir, and Lopinavir/Ritonavir in Antiretroviral-
Experienced HIV-Infected Children.
 Rudin C, Burri M, Shen Y, et al  
Pediatr Infect Dis J. 2008 Mar 2
 Abstract
 
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of
age: 24 week results.
 Chadwick EG, Capparelli EV, Yogev R, 
AIDS. 2008 Jan 11;22(2):249-255.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following
twice or once daily administration.
Rosso R, Di Biagio A, Dentone C, et al 
J Antimicrob Chemother. 2006 Apr 10;
 Abstract
 
     Conference Reports, Abstracts and Posters
 
  Long-term safety and effectiveness of ritonavir (RTV), nelfinavir (NFV) and lopinavir/
ritonavir (LPV/r) in antiretroviral (ARV) -experienced HIV-1-infected children
XVI  International AIDS Conference
 Abstract
 
Kaletra (lopinavir/ritonavir) on treatment of HIV infected children
G Jugulete , M Mardarescu, S Petrea, et al
 15IAC
)Abstract

LPV/RTV/D4T/3TC Studies
       

72 Week Data

     Conference Reports, Abstracts and Posters

  POSTER
Kaletra (ABT-378/ritonavir) in HIV-Infected Children at 72 Weeks.
Cahn P, Renz C, Saez-Lorens X, et al.
1st International AIDS Society Conference on HIV Pathogenesis and Treatment
Poster

60 Week Data

     Conference Reports, Abstracts and Posters

  POSTER
 Kaletra (ABT-378/ritonavir) in HIV-Infected Children at 60 Weeks
Saez-Llorens X, Renz C, Deetz C,  et al.  
 8th Conference on Retroviruses and Opportunistic Infections
 Poster
 
48 Week Data

     Journal Papers, Abstracts, and Commentaries
 
  Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in
human immunodeficiency virus-infected children.
 Saez-Llorens X, Violari A, Deetz CO, et al.
Pediatr Infect Dis J 2003 Mar;22(3):216-224
 Abstract

     Conference Reports, Abstracts and Posters

  Kaletra  (ABT-378/ritonavir) in HIV-Infected Children at 48 Weeks
Saez-Llorens X, Renz C, Deetz C, et al
 8th Conference on Retroviruses and Opportunistic Infections
 Abstract

LPV/RTV/EFV
       

    Journal Papers, Abstracts, and Commentaries

  Increased Dose of Lopinavir/Ritonavir Compensates for Efavirenz-Induced
Drug-Drug Interaction in HIV-1-Infected Children.
Bergshoeff AS, Fraaij PL, Ndagijimana J, et aL 
J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-68.
 Abstract

LPV/RTV/Multiple Drug Studies
       

     Journal Papers, Abstracts, and Commentaries

 
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of
age: 24 week results.
Chadwick EG, Capparelli EV, Yogev R, et al
AIDS. 2008 Jan 11;22(2):249-55.
 Abstract
 
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in
pre-treated vertically HIV-infected children.
 Larrú B, Resino S, Bellón JM, et al
J Antimicrob Chemother. 2007 Nov 19;
 Abstract
 
Long-term Follow-up of 414 HIV-Infected Romanian Children and Adolescents
Receiving Lopinavir/Ritonavir-Containing Highly Active Antiretroviral Therapy.
Kline MW, Rugina S, Ilie M, et al 
Pediatrics. 2007 Apr 9;
Abstract

Immunological Changes after Highly Active Antiretroviral Therapy with Lopinavir-
Ritonavir in Heavily Pretreated HIV-Infected Children.
Resino S, Galan I, Perez A, et al  
AIDS Res Hum Retroviruses. 2005 May;21(5):398-4
 Abstract
 
     Conference Reports, Abstracts and Posters
 
 
PDF POSTER
 Long-term Follow-up of 414 HIV-infected Romanian Children and Adolescents
Receiving Lopinavir/Ritonavir-containing HAART 
M Kline, S Rugina, M Ilie, et al
 14 CROI
 Poster
 
A Prospective Evaluation of Pharmacologic, Virologic, and Immunologic
Parameters of Lopinavir/Ritonavir for HIV-1-infected Infants < 6 Months of Age
EG Chadwick, J Rodman, P Palumbo, et al  
11th Conference on Retroviruses and Opportunistic Infections 
 Abstract

PDF POSTER
 Immunovirological outcome, genotypic changes and treatment adherence in
HIV-1 infected children under lopinavir/ritonavir therapy
 C Muñoz-Almagro, A Noguera , J Mallolas , et al.   
2nd European HIV Drug Resistance Workshop  March 11-13, 2004.
Poster
 
Impact of kaletra treatment in HIV-infected Children
 MM Castrejon , E Castano, O Suman
 (14IAC)
 Abstract
 
Response to lopinavir-ritonavir (Kaletra) in heavily pretreated children
J T Ramos, P Carreño , C Fortuny, et al
14IAC
 Abstract
 

  POSTER
Predictive Factors of Virological Success in PI-naive and -experienced HIV-infected
Children Treated with a Regimen Including Lopinavir/Ritonavir
C Delaugerre, JP Teglas, JM Treluyer, et al.  
11th Conference on Retroviruses and Opportunistic Infections 
 PDF Poster        Abstract  

Salvage Therapy Studies
       

     Journal Papers, Abstracts, and Commentaries

 
Positive virological outcome after lopinavir/ritonavir salvage therapy in protease
inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S, Bellon JM, Ramos JT, et al 
J Antimicrob Chemother. 2004 Oct 7
Abstract

Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily
pretreated HIV-1 vertically infected children.
Galan I, Jimenez JL, Gonzalez-Rivera M, et al
AIDS. 2004 Apr 12;18(2):247-255.
 Abstract
 
     Conference Reports, Abstracts and Posters
 
  Virological phenotype switches under salvage therapy with lopinavir-ritonavir in
heavily pretreated HIV-1 vertically infected children
I Galán, MI De José, M L Navarro, et al
15IAC
 Abstract
 
Positive virologic outcome after Lopinavir/ritonavir salvage therapy in protease
inhibitor-experienced HIV-1-infected children. A prospective cohort study
S Resino, J M Bellón, I Galán, et al
 15IAC
)Abstract
 
1 year follow up of salvage therapy (ST) with lopinavir/ritonavir and amprenavir based
combinations in children failing previous highly active anti-retroviral therapy (HAART)
regimens
M Mathur, E Handelsman, K Tizer, N Desai
 14IAC
Abstract

KLS Main Page

Home

 

Lopinavir/Ritonavir
Pediatric Indications: Efficacy